FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Elisabeth Iljas Heath

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Patricia M LoRusso; Lisa M Malburg; Richard A Messmann; Maryjo Pilat; Mary F Quinn; Susan L Bever; Martin J Edelman; Karen M Forman; Elisabeth Iljas Heath; Patrick J Klein; Christopher P Leamon; Jing Li; Edward A Sausville
Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.
Abdo J Najy; Allen Saliganan; Joshua J Won; R Daniel Bonfil; Michael L Cher; M Katie Conley-LaComb; Elisabeth Iljas Heath; Young Suk Jung; Chong Jai Kim; Hyeong-Reh Choi Kim
Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.
Elisabeth Iljas Heath; Lisa Malburg; A Benjamin Suttle; Laurel Adams; Howard Ball; Karen Forman; Shelby Gainer; Patricia M LoRusso
A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Elisabeth Iljas Heath (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Patricia M LoRusso; Lisa M Malburg; Richard A Messmann; Maryjo Pilat; Mary F Quinn; Susan L Bever; Martin J Edelman; Karen M Forman; Elisabeth Iljas Heath; Patrick J Klein; Christopher P Leamon; Jing Li; Edward A Sausville
Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(32):4011-6.
2012: Abdo J Najy; Allen Saliganan; Joshua J Won; R Daniel Bonfil; Michael L Cher; M Katie Conley-LaComb; Elisabeth Iljas Heath; Young Suk Jung; Chong Jai Kim; Hyeong-Reh Choi Kim
Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.
The Prostate 2012;72(12):1328-38.
2012: Elisabeth Iljas Heath; Lisa Malburg; A Benjamin Suttle; Laurel Adams; Howard Ball; Karen Forman; Shelby Gainer; Patricia M LoRusso
A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors.
Investigational new drugs 2012;30(4):1566-74.
2012: Naomi B Haas; Elisabeth Iljas Heath; Xinyi Lin; Glenn Liu; Judith Manola; David McDermott; David Nanus; Michael Pins; George Wilding; Janice Dutcher
A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802.
Medical oncology (Northwood, London, England) 2012;29(2):761-7.
2012: Vincent Chung; Elisabeth Iljas Heath; Jeffrey D Botbyl; Brendan M Johnson; Lyndon Kirby; Thomas A Lampkin; Kerlin M Lynch; William R Schelman; Kyle D Holen
First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer.
Cancer chemotherapy and pharmacology 2012;69(3):733-41.
2012: Steven M Lucas; Elisabeth Iljas Heath
Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers.
Prostate cancer 2012;2012():640968.
2012: Shin Ogita; Daryn Smith; Sheela Tejwani; Karen Baranowski; Joseph A Fontana; Stacy Freeman; Elisabeth Iljas Heath; Lance K Heilbrun; Ulka Nitin Vaishampayan
Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer.
ISRN oncology 2012;2012():242850.
2012: Dejuan Kong; Yiwei Li; Mani Menon; Isaac J Powell; Wael A Sakr; Seema Sethi; Shadan Ali; Wei Chen; Michael L Cher; Dhananjay Chitale; Nilesh Gupta; Oudai Hassan; Elisabeth Iljas Heath; Lance K Heilbrun; Clara Hwang; Asfar S Azmi
Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM.
PloS one 2012;7(3):e33729.
2012: Dejuan Kong; Yiwei Li; Mani Menon; Isaac J Powell; Wael A Sakr; Seema Sethi; Shadan Ali; Wei Chen; Michael L Cher; Dhananjay Chitale; Nilesh Gupta; Oudai Hassan; Elisabeth Iljas Heath; Lance K Heilbrun; Clara Hwang; Asfar S Azmi
Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment.
American journal of translational research 2012;4(1):14-23.
2011: Elisabeth Iljas Heath; Patricia M LoRusso; Suresh S Ramalingam; Manuel Valdivieso; Xiaofei Zhou; Tatiana Besse-Hamer; Fatima Cardoso; Merrill J Egorin; Teresa Has; Leila Alland; Ahmad Awada; Chandra P Belani
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.
Investigational new drugs 2011;29(6):1426-31.
2011: Madhuri Bajaj; Elisabeth Iljas Heath
Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults.
Expert opinion on biological therapy 2011;11(11):1519-24.
2011: Sachin Gupta; Elisabeth Iljas Heath; Lance K Heilbrun; Venkata Parsa; Daryn W Smith; Brenda Dickow; Ulka Nitin Vaishampayan
Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction.
Anti-cancer drugs 2011;22(8):794-800.
2011: Elisabeth Iljas Heath; Sindy T Kim; Noelle K Loconte; Patricia M LoRusso; Ana Ruiz-Garcia; George R Blumenschein; Richard C Chao; Roger B Cohen; George Wilding
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
Cancer chemotherapy and pharmacology 2011;68(3):703-12.
2011: Xiaohua Li; Fulvio Lonardo; Wael A Sakr; Asfar S Azmi; Elisabeth Iljas Heath; Jonathan Irish; Alexander Kaplun; Shijie Sheng
HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells.
Molecular cancer research : MCR 2011;9(6):733-45.
2010: Monica Mita; Matthew A Spear; Lorrin K Yee; Catalin Mita; Elisabeth Iljas Heath; Kyriakos P Papadopoulos; Kristine C Federico; Steven D Reich; Ofelia Romero; Lisa Malburg; MaryJo Pilat; G Kenneth Lloyd; Saskia T C Neuteboom; Gillian Cropp; Edward Ashton; Patricia M LoRusso
Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(23):5892-9.
2010: Elisabeth Iljas Heath; E G Chiorean; C J Sweeney; J P Hodge; J J Lager; K Forman; L Malburg; T Arumugham; M M Dar; A B Suttle; S D Gainer; Patricia M LoRusso
A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors.
Clinical pharmacology and therapeutics 2010;88(6):818-23.
2010: Qiang Zheng; Xianyi Sha; Jiansheng Liu; Elisabeth Iljas Heath; Patricia M LoRusso; Jing Li
Association of human cytochrome P450 1A1 (CYP1A1) and sulfotransferase 1A1 (SULT1A1) polymorphisms with differential metabolism and cytotoxicity of aminoflavone.
Molecular cancer therapeutics 2010;9(10):2803-13.
2010: Przemyslaw Twardowski; Walter M Stadler; Paul Frankel; Primo Lara; Christopher Ruel; Gurkamal Chatta; Elisabeth Iljas Heath; David I Quinn; David R Gandara
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.
Urology 2010;76(4):923-6.
2010: Joseph Paul Eder; Geoffrey I Shapiro; Leonard J Appleman; Andrew X Zhu; Dale Miles; Harold Keer; Belinda Cancilla; Felix Chu; Suzanne Hitchcock-Bryan; Laurie Sherman; Stewart McCallum; Elisabeth Iljas Heath; Scott A Boerner; Patricia M LoRusso
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(13):3507-16.
2010: Iftekhar U Ahmad; Jeffrey D Forman; Asfar S Azmi; Gilda G Hillman; Elisabeth Iljas Heath; Ulka Nitin Vaishampayan; Michael L Cher; Fundagul Andic; Peter J Rossi; Omer Kucuk
Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer.
Nutrition and cancer 2010;62(7):996-1000.
2010: Elisabeth Iljas Heath; Lance K Heilbrun; Jing Li; Ulka Nitin Vaishampayan; Felicity WK Harper; Pam Pemberton; Asfar S Azmi
A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer.
American journal of translational research 2010;2(4):402-11.
2010: Clara Hwang; Elisabeth Iljas Heath
Angiogenesis inhibitors in the treatment of prostate cancer.
Journal of hematology & oncology 2010;3():26.
2009: Cathryn Hufford Bock; Ann Grossbart Schwartz; Julie J Ruterbusch; Al Levin; Christine Neslund-Dudas; Susan J Land; Angela S Wenzlaff; David Reich; Paul McKeigue; Wei Chen; Elisabeth Iljas Heath; Isaac J Powell; Rick Kittles; Benjamin A Rybicki
Results from a prostate cancer admixture mapping study in African-American men.
Human genetics 2009;126(5):637-42.
2009: Emmanuel S Antonarakis; Elisabeth Iljas Heath; JANET WALCZAK; William G Nelson; Helen Fedor; Angelo M DeMarzo; Marianna L Zahurak; Steven Piantadosi; Andrew J Dannenberg; Robin T Gurganus; Sharyn D Baker; Howard L Parnes; Theodore L DeWeese; Alan W Partin; Michael A Carducci
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):4986-93.
2009: Elisabeth Iljas Heath
ALK inhibitors in lung cancer.
Clinical advances in hematology & oncology : H&O 2009;7(10):649-50.
2009: Richard Wiegand; Jianmei Wu; Xianyi Sha; Patricia M LoRusso; Elisabeth Iljas Heath; Jing Li
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate aminoflavone (NSC 686288) in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(14-15):1460-4.
2009: Elisabeth Iljas Heath; Patricia M LoRusso; S Percy Ivy; Larry Rubinstein; Michaele C Christian; Lance K Heilbrun
Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience.
Journal of biopharmaceutical statistics 2009;19(3):414-23.
2009: Albert O Shar; Marie A Gaudard; Elisabeth Iljas Heath; Arlene A Forastiere; Yang Vincent; Stephen J Sontag
Modeling using baseline characteristics in a small multicenter clinical trial for Barrett's esophagus.
Contemporary clinical trials 2009;30(1):2-7.
2008: Elisabeth Iljas Heath; David W Hillman; Ulka Nitin Vaishampayan; Shijie Sheng; Asfar S Azmi; Felicity WK Harper; Melvin Gaskins; Henry C Pitot; Winston Tan; S Percy Ivy; Roberto Pili; Michael A Carducci; Charles Erlichman; Glenn Liu
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7940-6.
2008: Patricia M LoRusso; Elisabeth Iljas Heath; Jesse McGreivy; Yu-Nien Sun; Rebeca Melara; Lucy Yan; Lisa Malburg; Megan Ingram; Jeffrey Wiezorek; Li Chen; Mary Jo Pilat
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors.
Investigational new drugs 2008;26(5):455-62.
2008: Duyen T Dang; SY Chun; Kyunghee Burkitt; Masako Abe; Shaowei Chen; Pamela Havre; Nicola J Mabjeesh; Elisabeth Iljas Heath; Nicholas J Vogelzang; Marcia Cruz-Correa; Douglas W Blayney; William D Ensminger; Brad St Croix; Nam H Dang; Long H Dang
Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.
Cancer research 2008;68(6):1872-80.
2008: JASON DANIELS; Michael K Gibson; Li Xu; Shaoli Sun; Marcia Canto; Elisabeth Iljas Heath; JEAN WANG; Malcolm V Brock; Elizabeth Montgomery
Gastrointestinal tract epithelial changes associated with taxanes: marker of drug toxicity versus effect.
The American journal of surgical pathology 2008;32(3):473-7.
2008: Elisabeth Iljas Heath; Keith Bible; Robert E Martell; Daniel C Adelman; Patricia M LoRusso
A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.
Investigational new drugs 2008;26(1):59-65.
2008: A O Shar; Marie A Gaudard; Elisabeth Iljas Heath; Arlene A Forastiere; Yang Vincent; Stephen J Sontag
Quantitative endoscopy in the chemoprevention of Barrett's Esophagus Trial.
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus / I.S.D.E 2008;21(7):641-4.
2008: Elisabeth Iljas Heath; Michael W Kattan; Isaac J Powell; Wael A Sakr; Timothy C Brand; Benjamin A Rybicki; Ian M Thompson; William J Aronson; Martha Kennedy Terris; Christopher J Kane; Joseph C Presti; Christopher L Amling; Stephen J Freedland
The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer.
Urology 2008;71(1):151-5.
2008: Soley Seren; Ronald Lieberman; Ulas D Bayraktar; Elisabeth Iljas Heath; Kazim Sahin; Fundagul Andic; Omer Kucuk
Lycopene in cancer prevention and treatment.
American journal of therapeutics 2008;15(1):66-81.
2008: Priya G Kumaravelu; Sandra Vella; J Edson Pontes; Elisabeth Iljas Heath
Malignant undifferentiated sex cord-stromal testis tumor with brain metastasis: case report.
Urologic oncology 2008;26(1):53-5.
2007: Linda E Bröker; Stephan A Veltkamp; Elisabeth Iljas Heath; Bart C Kuenen; Helen Gall; Ludovic Astier; Susan Parker; Louis Kayitalire; Patricia M LoRusso; Jan H M Schellens; Giuseppe Giaccone
A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(13):3906-12.
2007: Elisabeth Iljas Heath; Marcia Canto; Steven Piantadosi; Elizabeth Montgomery; Wilfred M Weinstein; James G Herman; Andrew J Dannenberg; Yang Vincent; Albert O Shar; Ernest T Hawk; Arlene A Forastiere
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.
Journal of the National Cancer Institute 2007;99(7):545-57.
2007: Shirish M Gadgeel; John Ruckdeschel; Elisabeth Iljas Heath; Lance K Heilbrun; Raghu Venkatramanamoorthy; Antoinette J Wozniak
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(4):299-305.
2006: Elisabeth Iljas Heath; Michael A Carducci
New targets in the management of prostate cancer.
Hematology/oncology clinics of North America 2006;20(4):985-99, xi.
2006: Elisabeth Iljas Heath; Barbara Burtness; Lawrence Kleinberg; Ronald R Salem; Stephen C Yang; Richard F Heitmiller; Marcia Canto; Jonathan Knisely; Mark D Topazian; Elizabeth Montgomery; Nancy Tsottles; Yazdi K Pithavala; Bridget Rohmiller; Mary Collier; Arlene A Forastiere
Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma.
Investigational new drugs 2006;24(2):135-40.
2005: Elisabeth Iljas Heath; Melvin Gaskins; Henry C Pitot; Roberto Pili; Winston Tan; Robert Marschke; Glenn Liu; David Hillman; Asfar S Azmi; Shijie Sheng; Charles Erlichman; Percy Ivy
A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
Clinical prostate cancer 2005;4(2):138-41.
2004: Mingzhou Guo; Yoshimitsu Akiyama; Michael G House; Craig M Hooker; Elisabeth Iljas Heath; Edward Gabrielson; Stephen C Yang; Yu Han; Stephen B Baylin; James G Herman; Malcolm V Brock
Hypermethylation of the GATA genes in lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(23):7917-24.
2004: Mingzhou Guo; Michael G House; Craig M Hooker; Yu Han; Elisabeth Iljas Heath; Edward Gabrielson; Stephen C Yang; Stephen B Baylin; James G Herman; Malcolm V Brock
Promoter hypermethylation of resected bronchial margins: a field defect of changes?
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):5131-6.
2004: Ying Hao; Fule Zhou; Anthony F Shields; Otto Muzik; Dafang Wu; Elisabeth Iljas Heath
A novel computerized approach to enhancing lung tumor detection in whole-body PET images.
Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference 2004;3():1589-92.
2003: Michael K Gibson; Susan C Abraham; Tsung-Teh Wu; Barbara Burtness; Richard F Heitmiller; Elisabeth Iljas Heath; Arlene A Forastiere
Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(17):6461-8.
2003: Lawrence Kleinberg; Jonathan Knisely; Richard F Heitmiller; Marriana Zahurak; Ronald Salem; Barbara Burtness; Elisabeth Iljas Heath; Arlene A Forastiere
Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.
International journal of radiation oncology, biology, physics 2003;56(2):328-34.
2003: Elisabeth Iljas Heath; Marcia Canto; Tsung-Teh Wu; Steven Piantadosi; Ernest T Hawk; Aynur Unalp; G Gordon; Arlene A Forastiere
Chemoprevention for Barrett's esophagus trial. Design and outcome measures.
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus / I.S.D.E 2003;16(3):177-86.
2002: Elisabeth Iljas Heath; Theodore L DeWeese; Alan W Partin; Angelo M DeMarzo; John Groopman; William G Nelson; Steven Piantadosi; Ron Lieberman; Michael A Carducci
The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate.
Clinical prostate cancer 2002;1(3):182-7.
2002: John R Doty; Jorge D Salazar; Arlene A Forastiere; Elisabeth Iljas Heath; Lawrence Kleinberg; Richard F Heitmiller
Postesophagectomy morbidity, mortality, and length of hospital stay after preoperative chemoradiation therapy.
The Annals of thoracic surgery 2002;74(1):227-31; discussion 231.
2002: Elisabeth Iljas Heath; Susan G Urba; John Marshall; Steven Piantadosi; Arlene A Forastiere
Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus.
Investigational new drugs 2002;20(1):95-9.
2001: Elisabeth Iljas Heath; Seamus O'Reilly; R Humphrey; P Sundaresan; Ross C Donehower; SE Sartorius; M John Kennedy; Deborah K Armstrong; Michael A Carducci; J M Sorensen; K Kumor; S Kennedy; Louise B. Grochow
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2001;48(4):269-74.
2001: Paul G Corn; Elisabeth Iljas Heath; Richard F Heitmiller; Franz Fogt; Arlene A Forastiere; James G Herman; Tsung-Teh Wu
Frequent hypermethylation of the 5' CpG island of E-cadherin in esophageal adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(9):2765-9.
2001: Elisabeth Iljas Heath; Arlene A Forastiere
Therapy for esophageal cancer.
Cancer treatment and research 2001;105():387-98.
2000: Y W Choi; Elisabeth Iljas Heath; Richard F Heitmiller; Arlene A Forastiere; Tsung-Teh Wu
Mutations in beta-catenin and APC genes are uncommon in esophageal and esophagogastric junction adenocarcinomas.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2000;13(10):1055-9.
2000: Elisabeth Iljas Heath; Howard S Kaufman; Mark A Talamini; Tsung-Teh Wu; Jane H. Wheeler; Richard F Heitmiller; Lawrence Kleinberg; Stephen C Yang; K Olukayode; Arlene A Forastiere
The role of laparoscopy in preoperative staging of esophageal cancer.
Surgical endoscopy 2000;14(5):495-9.
2000: Elisabeth Iljas Heath; Louise B. Grochow
Clinical potential of matrix metalloprotease inhibitors in cancer therapy.
Drugs 2000;59(5):1043-55.
2000: Amitabh Chak; Marcia Canto; Gregory Scott Cooper; G Isenberg; J Willis; Nathan Levitan; Julie Clayman; Arlene A Forastiere; Elisabeth Iljas Heath; M V Sivak
Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients.
Cancer 2000;88(8):1788-95.
2000: Elisabeth Iljas Heath; Paul J Limburg; Ernest T Hawk; Arlene A Forastiere
Adenocarcinoma of the esophagus: risk factors and prevention.
Oncology (Williston Park, N.Y.) 2000;14(4):507-14; discussion 518-20, 522-3.
2000: Elisabeth Iljas Heath; Barbara Burtness; Richard F Heitmiller; Ronald Salem; Lawrence Kleinberg; Jonathan Knisely; Stephen C Yang; Mark A Talamini; Howard S Kaufman; Marcia Canto; Mark D Topazian; Tsung-Teh Wu; K Olukayode; Arlene A Forastiere
Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(4):868-76.
1999: H Shiga; Elisabeth Iljas Heath; AA Rasmussen; Bruce J Trock; P G Johnston; Arlene A Forastiere; M Langmacher; Alfred E Baylor; M Lee; Kevin J Cullen
Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4097-104.
1999: Elisabeth Iljas Heath; J T Holbrook; Arlene A Forastiere
Gastroesophageal reflux and adenocarcinoma of the esophagus.
The New England journal of medicine 1999;341(7):536-7; author reply 537-8.